Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Levy

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
Medicine|July 22, 2016
Digestive-tract sarcoidosis: French nationwide case-control study of 25 casesEtienne Ghrenassia, Arsene Mekinian, Catherine Chapelon-Albric, et al.
European Journal of Internal Medicine|August 23, 2020
ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countriesAlexander T Cohen, Ulrich Hoffmann, Philippe Hainaut, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)|December 13, 2018
Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) studyRaffaele De Caterina, Peter Kelly, Pedro Monteiro, et al.
Autoimmunity Reviews|January 25, 2015
The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective studyArsène Mekinian, Maria Grazia Lazzaroni, Anna Kuzenko, et al.
Thrombosis Research|September 20, 2020
ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 monthsGiancarlo Agnelli, Ulrich Hoffmann, Philippe Hainaut, et al.
BMC Cardiovascular Disorders|July 14, 2019
Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe)Raffaele De Caterina, Peter Kelly, Pedro Monteiro, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|July 26, 2022
Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical carePaulus Kirchhof, Ladislav Pecen, Ameet Bakhai, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|August 14, 2020
Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe studyJoris R de Groot, Thomas W Weiss, Peter Kelly, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|November 23, 2019
Economic evaluation of meningococcal vaccines: considerations for the futureHannah Christensen, Hareth Al-Janabi, Pierre Levy, et al.
Thrombosis Journal|June 2, 2018
Correction to: Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) studyAlexander T Cohen, Cihan Ay, Philippe Hainaut, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Medicine|July 22, 2016
Digestive-tract sarcoidosis: French nationwide case-control study of 25 casesEtienne Ghrenassia, Arsene Mekinian, Catherine Chapelon-Albric, et al.
European Journal of Internal Medicine|August 23, 2020
ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countriesAlexander T Cohen, Ulrich Hoffmann, Philippe Hainaut, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)|December 13, 2018
Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) studyRaffaele De Caterina, Peter Kelly, Pedro Monteiro, et al.
Autoimmunity Reviews|January 25, 2015
The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective studyArsène Mekinian, Maria Grazia Lazzaroni, Anna Kuzenko, et al.
Thrombosis Research|September 20, 2020
ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 monthsGiancarlo Agnelli, Ulrich Hoffmann, Philippe Hainaut, et al.
BMC Cardiovascular Disorders|July 14, 2019
Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe)Raffaele De Caterina, Peter Kelly, Pedro Monteiro, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|July 26, 2022
Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical carePaulus Kirchhof, Ladislav Pecen, Ameet Bakhai, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|August 14, 2020
Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe studyJoris R de Groot, Thomas W Weiss, Peter Kelly, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|November 23, 2019
Economic evaluation of meningococcal vaccines: considerations for the futureHannah Christensen, Hareth Al-Janabi, Pierre Levy, et al.
Thrombosis Journal|June 2, 2018
Correction to: Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) studyAlexander T Cohen, Cihan Ay, Philippe Hainaut, et al.
Pageof 8